Representation from all the key disciplines — toxicology, pharmacovigilance, clinical research, pharmacology, manufacturing, legal, and, yes, marketing — is essential for drug-development success today. A cross-functional model allows companies to bridge the gap between R&D and commercialization to bring products to market quicker and more efficiently.
PharmaVOICE interviewed four cross-functional teams for this month’s Forum. Representatives from MedImmune, Wyeth, Novartis, and Kalypsys provide insights into what makes multidisciplinary teams successful…
Best Practices for Cross-Functional Team Success
Sound Bites from the Field:
Stephen Cutler, Senior VP, Global Project Management, Quintiles Transnational Corp. For more information, visit quintiles.com.
Gregg Dearhammer, President, i3 Statprobe. For more information, visit i3statprobe.com.
Gloria Gibbons, Regional President, Europe, Ogilvy Healthworld. For more information, visit ogilvyhealthworld.com.
John Kane, Principal and Managing Director, Kane and Finkel Healthcare Communications. For more information, visit kaneandfinkel.com.
Susan Miller, Partner, The CementWorks LLC. For more information, visit thecementworks.com.
Mychelle Mowry, VP for Global Health Industries, Oracle Corp. For more information, visit oracle.com.
John Racik, President and CEO, Stonefly Communications Group. For more information, visit stoneflygroup.com.
Hanneke Schreurs, Senior VP, Global Project Management, Omnicare Clinical Research. For more information, visit omnicarecr.com.
Peter Sowood, M.D., Ph.D., President, Icon Clinical Research, Europe. For more information, visit iconclinical.com.
Steve Viviano, President of Integrated Communications Corp. For more information, visit icclink.com.
George Cox, Senior Director, Supply Chain, Manufacturing
George W. Kemble, Ph.D., VP, R&D, Vaccines
Michael Massaro, Director, Strategic Operations
Alan Taggart, Influenza Vaccines Program Manager
Nick Tressler, Manager, Operations Business Support Team, Finance
Lota S. Zoth, Senior VP and Chief Financial Officer
Damon L. Bass, D.O., FACR, Associate Director, Inflammation, Clinical Research & Development
F. Owen Fields, Ph.D., Director II, Global Regulatory Affairs
William Jacobson, Ph.D., Director, Project Management, Women’s Health & Pharma Business Units
Robert H. Michel, Director, New Products, Women’s Health Care
Daniel Curtis, Ph.D., Investigator, Developmental and Molecular Pathways
Peter Finan, Ph.D., Director, Pathway Biology, Developmental and Molecular Pathways
Mark Fishman, M.D., President of NIBR
John A. Tallarico, Ph.D., Head of Chemogenetics, Global Discovery Chemistry Group
Chris Hassig, Ph.D., Principal Scientist in the company’s biology department and project leader for the KD7040 Topical Gel program for neuropathic pain
John McKearn, Ph.D., President and CEO
Shawn Scranton, Pharm.D., Director of Clinical Development